Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Liliya Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2023-173499

Published: 2023

Journal Articles

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger

Blood (2022) 140 (Supplement 1): 9663–9664.

https://doi.org/10.1182/blood-2022-156889

Published: 2022

Journal Articles

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2021) 138 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2021-152328

Published: 2021

Journal Articles

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Heinz Gisslinger, MD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, MD, Petr Dulicek, MD, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiří Mayer, Vera Yablokova, MD, Kurt Krejcy, MD, Victoria Empson, MSc, Hans C. Hasselbalch, MD, Robert Kralovics, PhD, Jean Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136973

Published: 2020

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Arpad Illes, MD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, Professor, dr.MD, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 579.

https://doi.org/10.1182/blood-2018-99-118715

Published: 2018

Journal Articles

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva, MD PhD, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sicheva, Jiri Mayer, Prof, MD SCs, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, MD Professor, DMSc, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2017) 130 (Supplement 1): 320.

https://doi.org/10.1182/blood.V130.Suppl_1.320.320

Published: 2017

Journal Articles

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, MD, Christoph Klade, Pencho Georgiev, Aleksander Skotnicki, MD PhD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, Arpad Illes, MD PhD, Halyna Pylypenko, MD, Liliya Sivcheva, Jiri Mayer, MD, Barbara Grohmann-Izay, MD, Hans Hasselbalch, MD, Robert Kralovics, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 475.

https://doi.org/10.1182/blood.V128.22.475.475

Published: 2016

Journal Articles

Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide,

Jiri Schwarz, MD, PhD, Miroslav Penka, MD, PhD, Petra Ovesna, PhD, Olga Cerna, MD, Yvona Brychtova, MD, Petr Dulicek, MD, PhD

Blood (2011) 118 (21): 3857.

https://doi.org/10.1182/blood.V118.21.3857.3857

Published: 2011

Journal Articles

JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia

Miroslav Penka, Jiri Schwarz, Michael Doubek, MD, PhD, Petr Dulicek, Karel Indrak, Yvona Brychtova, MD, Antonin Hlusí, Jarmila Kissova, Jiri Mayer, MD, Tomas Pavlik

Blood (2008) 112 (11): 5257.

https://doi.org/10.1182/blood.V112.11.5257.5257

Published: 2008

Journal Articles

The Frequency of Venous Thromboembolism in Women with F V Leiden in Heterozygous Form from the East Bohemia Region in Association with Pregnancy and Puerperium.

Petr Dulicek, M.D., Ph.D., Pavel Zak, M.D., Ph.D., Jaroslav Maly, M.D., Ph.D., Miroslav Pecka, M.D., Ph.D., Vladimir Maisnar, M.D., Ph.D., Martin Beranek, M.D.

Blood (2004) 104 (11): 4006.

https://doi.org/10.1182/blood.V104.11.4006.4006

Published: 2004

NARROW

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide,

JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia

The Frequency of Venous Thromboembolism in Women with F V Leiden in Heterozygous Form from the East Bohemia Region in Association with Pregnancy and Puerperium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only